[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Al-Azhar University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":606},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,106,0,25,[9,39,62,85,108,128,149,171,193,219,242,268,287,310,340,362,385,412,435,463,489,510,532,553,579],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100652482","endothelial-markers-and-tadalafil-response-100652482",false,"NCT07773103","Endothelial Markers and Tadalafil Response","Endothelial Dysfunction Markers as Predictors of Clinical Response to Daily Tadalafil in Men With Vasculogenic Erectile Dysfunction","Inclusion Criteria:\n\n* Participants must fulfill all of the following:\n\n  * Men aged 30 to 70 years.\n  * ED lasting at least 3 months.\n  * IIEF-5\u002FSHIM score of 21 or less or clinically documented ED.\n  * Clinical features suggesting predominantly vasculogenic ED.\n  * Sexually active or willing to attempt sexual intercourse during the study.\n  * Able to complete the study questionnaires.\n  * Willing to take tadalafil 5 mg once daily for 12 weeks.\n  * Able to provide written informed consent.\n  * Willing to avoid other ED treatments during the study unless medically necessary.\n\nExclusion Criteria:\n\n* Patients will be excluded if they have:\n\n  * ED primarily attributed to psychogenic causes.\n  * Predominantly neurogenic ED.\n  * Severe untreated hypogonadism likely to be the primary cause of ED.\n  * Untreated hyperprolactinemia or another major endocrine disorder.\n  * Significant penile anatomical abnormality interfering with intercourse, including severe Peyronie's disease.\n  * Previous radical pelvic surgery or pelvic radiotherapy.\n  * Active urinary or genital infection.\n  * Unstable angina or unstable cardiovascular disease.\n  * Recent myocardial infarction or stroke.\n  * Uncontrolled hypertension or clinically significant hypotension.\n  * Severe renal impairment requiring an alternative tadalafil regimen.\n  * Severe hepatic impairment.\n  * Active malignancy or expected survival of less than one year.\n  * Major psychiatric illness, cognitive impairment or inability to comply with follow-up.\n  * Current use of another PDE5 inhibitor or intracavernosal therapy that cannot be discontinued.\n  * Concomitant use of organic nitrates, nitric oxide donors or nicorandil.\n  * Known hypersensitivity to tadalafil.\n  * Participation in another study that may affect erectile function or vascular measurements.\n  * Refusal or inability to provide informed consent.","MALE","30 Years","70 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","This prospective cohort study will recruit eligible men attending the Urology\u002FAndrology outpatient clinic. Baseline assessment will include demographic and clinical data, cardiovascular risk assessment, erectile-function questionnaires, routine laboratory investigations, brachial artery flow-mediated dilatation, carotid intima-media thickness, and selected circulating endothelial biomarkers including endothelin-1, nitrite\u002Fnitrate, high-sensitivity C-reactive protein, soluble vascular cell adhesion molecule-1, and soluble intercellular adhesion molecule-1. All participants will receive tadalafil 5 mg once daily for 12 weeks. Erectile function, adherence, and adverse events will be assessed during follow-up. The primary outcome will be clinical response at 12 weeks, defined as an improvement of at least 4 points in the IIEF-EF domain together with a positive response to the Global Assessment Question.",[26],"Vasculogenic Erectile Dysfunction","RECRUITING","2026-08-19",{"date":30,"type":31},"2026-08-20","ACTUAL",{"date":28,"type":31},{"date":34,"type":22},"2028-12",{"name":36,"class":37},"Al-Azhar University","OTHER",1,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":38},"100652436","pre-stenting-in-miniaturized-rirs-100652436","NCT07773090","Role of Pre-stenting Before Retrograde Intrarenal Surgery With Miniaturized Flexible Ureteroscopes","Does Pre-stenting Still Have a Role in Retrograde Intrarenal Surgery in the Era of Miniaturized Flexible Ureteroscopes? Surgical Outcomes From a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  * Adults aged 18-70 years.\n  * Unilateral renal calculi.\n  * Maximum total renal stone burden of 10-20 mm.\n  * Planned treatment with RIRS.\n  * Suitable candidate for elective endoscopic stone treatment.\n  * Negative or appropriately treated preoperative urine culture.\n  * Ability to provide written informed consent.\n  * Ability and willingness to comply with postoperative follow-up, including non-contrast CT at 4 weeks after the final RIRS procedure.\n\nExclusion Criteria:\n\n* Participants will be excluded for any of the following:\n\n  * Bilateral renal calculi requiring simultaneous surgical treatment.\n  * Active urinary tract infection, sepsis, or infected obstruction requiring urgent drainage.\n  * Solitary kidney when randomization is considered clinically unsafe.\n  * Known ureteral stricture or congenital ureteral abnormality likely to interfere with ureteroscopic access.\n  * Previous failed ipsilateral ureteroscopic access requiring clinically indicated pre-stenting.\n  * Existing ipsilateral ureteral stent or nephrostomy.\n  * Previous ureteral reconstruction or urinary diversion.\n  * Total renal stone burden greater than 20 mm.\n  * Staghorn calculi.\n  * Uncorrected coagulopathy.\n  * Pregnancy.\n  * Severe uncorrected cardiopulmonary disease precluding anesthesia.\n  * Inability or unwillingness to provide informed consent.\n  * Inability or unwillingness to comply with follow-up.\n  * Any other condition judged by the treating surgeon to make randomization or RIRS clinically inappropriate or unsafe.","ALL","18 Years",{"count":49,"type":22},270,"INTERVENTIONAL",[52],"NA","This prospective randomized controlled trial will compare retrograde intrarenal surgery performed after routine preoperative ureteral stenting with direct retrograde intrarenal surgery without planned preoperative stenting in adults with unilateral renal calculi measuring 10-20 mm. The study will evaluate stone-free rate, ureteral access, need for rescue stenting, operative outcomes, complications, staged procedures, postoperative recovery, and auxiliary treatment.",[55],"Renal Calculi",{"date":57,"type":31},"2026-08-21",{"date":28,"type":31},{"date":60,"type":22},"2028-11-01",{"name":36,"class":37},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":12,"sex":46,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":50,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":38},"100652577","bedtime-device-restriction-and-desmopressin-in-pmne-100652577","NCT07776977","Bedtime Device Restriction and Desmopressin in PMNE.","Effect of Bedtime Digital-Device Restriction on the Therapeutic Response to Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 6-14 years.\n* Diagnosis of PMNE (≥2 wet nights\u002Fweek for ≥6 months, no daytime symptoms, no prior sustained dryness \\>6 months).\n* Willingness to take oral desmopressin nightly for 8 weeks.\n* Parent\u002Fguardian able to monitor and report screen time and wet nights.\n* Written informed consent from parent\u002Fguardian and assent from child (if age-appropriate).\n\nExclusion Criteria:\n\n* Secondary enuresis or non-monosymptomatic enuresis (daytime incontinence, urgency, frequency).\n* Known organic causes (e.g., diabetes mellitus, urinary tract anomalies, neurological disorders).\n* Current use of other enuresis treatments (alarms, anticholinergics, imipramine) within 4 weeks prior to enrollment.\n* Severe sleep disorders (e.g., obstructive sleep apnea) or psychiatric conditions affecting compliance.\n* Inability to comply with study procedures or follow-up.","6 Years","14 Years",{"count":72,"type":22},140,[52],"This randomized controlled trial will evaluate whether restricting bedtime digital-device use improves the response to desmopressin in children with primary monosymptomatic nocturnal enuresis. Participants will receive desmopressin for 8 weeks and will be assigned to either bedtime device restriction or usual screen habits.",[76],"Primary Monosymptomatic Nocturnal Enuresis","NOT_YET_RECRUITING","2026-08-18",{"date":30,"type":31},{"date":81,"type":22},"2026-08",{"date":83,"type":22},"2027-07",{"name":36,"class":37},{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":38},"100651965","long-term-safety-of-uas-assisted-vs-sheathless-rirs-in-non-prestented-patients-100651965","NCT07767773","Long-term Safety of UAS-assisted vs Sheathless RIRS in Non-prestented Patients","Long-Term Safety Outcomes of Ureteral Access Sheath-Assisted Versus Sheathless Retrograde Intrarenal Surgery for Renal Stones ≤20 mm in Non-Prestented Patients: A Retrospective Comparative Cohort Study With Active Follow-up","Inclusion Criteria:\n\n* Age ≥18 years at time of index RIRS.\n* Primary RIRS performed at Al-Azhar University Hospitals between Jan 1, 2020 and Dec 31, 2025.\n* Renal stone(s) with maximum diameter ≤20 mm on preoperative imaging.\n* No ipsilateral ureteral stent or nephrostomy before index RIRS.\n* Documented operative record specifying whether a UAS was used.\n* At least 12 months elapsed since index RIRS.\n* Available contact information allowing invitation for active follow-up.\n\nExclusion Criteria:\n\n* Primary ureteral stone treated during the same procedure.\n* Staghorn or \\>20 mm stone burden.\n* Prior ipsilateral ureteral stricture or reconstructive surgery.\n* Congenital renal\u002Fureteral anomalies affecting outcome (e.g., horseshoe kidney, duplicated system).\n* Incomplete operative or preoperative imaging records that preclude determination of eligibility or exposure (UAS use).\n* Additional ipsilateral ureteral procedure during follow-up that independently causes ureteral narrowing.\n* Refusal to participate in active follow-up or failure to attend after repeated attempts.",{"count":93,"type":22},1200,"This retrospective comparative cohort study will include adult patients who underwent primary RIRS for renal stones ≤20 mm at Al-Azhar University Hospitals between January 2020 and December 2025. Patients will be classified by whether a ureteral access sheath (UAS) was used during the index RIRS, and all eligible patients will be invited for active long-term follow-up (minimum 12 months) to assess the composite outcome of delayed ipsilateral ureteral stricture or new\u002Fprogressive ipsilateral hydronephrosis and other safety and efficacy outcomes. Propensity-score methods and adjusted regression analyses will be used to control confounding.",[96,97,98,99,100,101],"Renal Stone Disease","Ureteral Stricture","Hydronephrosis","Urolithiasis","Retrograde Intrarenal Surgery","Ureteral Access Sheath","2026-08-16",{"date":78,"type":31},{"date":102,"type":31},{"date":106,"type":22},"2027-12-25",{"name":36,"class":37},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":115,"targetDuration":117,"studyType":23,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":38},"100651320","risk-factors-and-clinical-implications-of-double-j-ureteral-stent-bacterial-colonization-100651320","NCT07760792","Risk Factors and Clinical Implications of Double-J Ureteral Stent Bacterial Colonization","Risk Factors and Clinical Implications of Double-J Ureteral Stent Bacterial Colonization: A Prospective Cohort Study","Inclusion Criteria:\n\n* Age 18 years or older.\n* Temporary Double-J stent insertion.\n* Standard urological indication.\n* Planned stent removal during follow-up.\n* Ability to attend follow-up and provide specimens.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Active urosepsis at insertion.\n* Permanent or intended long-term stenting.\n* Concomitant nephrostomy tube or urinary diversion.\n* Severe immunosuppression or neutropenia.\n* Incomplete baseline data.\n* Loss to follow-up or failure to retrieve the stent.\n* Refusal to participate.",{"count":116,"type":22},300,"48 Weeks","This prospective cohort study will evaluate the risk factors associated with bacterial colonization of Double-J ureteral stents and examine its clinical implications. Adult patients undergoing temporary ureteral stent insertion for routine urological indications will be followed until stent removal, when urine and stent cultures will be obtained. The study will assess the association between colonization and factors such as indwelling time, diabetes mellitus, chronic kidney disease, prior urinary tract infection, prior antibiotic exposure, and stent-related symptoms.",[120,121],"Bacterial Colonization","Double-J Ureteral Stents",{"date":78,"type":31},{"date":124,"type":31},"2026-08-10",{"date":126,"type":22},"2027-07-30",{"name":36,"class":37},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":47,"maxAge":19,"enrollmentInfo":135,"targetDuration":4,"studyType":50,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":38},"100650886","daily-tadalafil-as-adjunctive-therapy-versus-monotherapy-for-pde5-inhibitor-resistant-erectile-dysfunction-100650886","NCT07753720","Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction","Efficacy of Daily 5-mg Tadalafil as Adjunctive Therapy Versus Monotherapy in Men With On-Demand PDE5 Inhibitor-Resistant Erectile Dysfunction: A Prospective Randomized Trial","Inclusion Criteria\n\n* Age: 18 to 70 years.\n* Diagnosis: Erectile dysfunction for at least 6 months.\n* PDE5 inhibitor resistance: History of on-demand PDE5 inhibitor use for at least 3 months with inadequate response, defined as:\n* International Index of Erectile Function-Erectile Function score less than 26 despite optimal dosing.\n* Self-reported inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse in at least 50% of attempts.\n* Confirmed proper medication use with at least 4 to 8 attempts with adequate sexual stimulation.\n* Stable relationship: Sexually active with a female partner for at least 6 months.\n* Informed consent: Willing and able to provide written informed consent.\n\nExclusion Criteria\n\n* Current use of nitrates.\n* Unstable cardiovascular disease, including recent myocardial infarction within 6 months, unstable angina, or severe heart failure.\n* Uncontrolled hypertension greater than 180 over 110 mmHg or severe hypotension less than 90 over 50 mmHg.\n* Severe hepatic impairment, Child-Pugh class C, or renal impairment with estimated glomerular filtration rate less than 30 mL per minute per 1.73 m².\n* Untreated hypogonadism, total testosterone less than 250 ng\u002FdL.\n* Severe penile anatomic deformity or prior penile prosthesis.\n* History of priapism.\n* Severe untreated depression.\n* Pelvic surgery or radiation within 6 months.",{"count":136,"type":22},260,[138],"PHASE4","This randomized trial will compare daily tadalafil 5 mg as adjunct therapy versus monotherapy in men with on-demand PDE5 inhibitor-resistant erectile dysfunction. The study will evaluate changes in erectile function, treatment satisfaction, partner satisfaction, and safety over 12 weeks.",[141,142],"Erectile Dysfunction","Tadalafil",{"date":78,"type":31},{"date":145,"type":31},"2026-08-13",{"date":147,"type":22},"2027-06-30",{"name":36,"class":37},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":19,"enrollmentInfo":156,"targetDuration":4,"studyType":50,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":168,"leadSponsor":170,"locationsCount":38},"100650811","flexible-nephroscopy-assisted-single-tract-versus-multi-tract-percutaneous-nephrolithotomy-for-complex-renal-stones-100650811","NCT07753733","Flexible Nephroscopy-Assisted Single-Tract Versus Multi-Tract Percutaneous Nephrolithotomy for Complex Renal Stones","Flexible Nephroscopy-Assisted Single-Tract Versus Multi-Tract Percutaneous Nephrolithotomy for Complex Renal Stones: A Prospective, Randomized, Non-Inferiority Trial","Inclusion Criteria:\n\n* Age 18-70 years.\n\nUnilateral complex renal stones defined by one or more of the following: Guy's Stone Score III-IV, S.T.O.N.E. score ≥9, staghorn or partial staghorn calculus, or stones involving at least 3 calyces on NCCT.\n\nPreoperative expectation of multiple accesses by the surgeon.\n\nWritten informed consent.\n\nExclusion Criteria:\n\nSolitary kidney.\n\nUncorrected coagulopathy.\n\nActive urinary tract infection.\n\nASA grade IV or higher.\n\nPregnancy.\n\nPrevious ipsilateral PCNL or open renal surgery.\n\nStones less than 2 cm or simple calyceal stones.\n\nRefusal or inability to comply with follow-up.\n\n\\-",{"count":157,"type":22},470,[52],"This randomized, parallel-group, non-inferiority trial will compare flexible nephroscopy-assisted single-tract percutaneous nephrolithotomy with conventional multi-tract percutaneous nephrolithotomy in patients with complex unilateral renal stones. The primary outcome is stone-free rate at 3 months, and secondary outcomes include operative time, fluoroscopy time, hemoglobin drop, transfusion rate, hospital stay, complications, need for auxiliary procedures, and cost-effectiveness.",[161],"Percutaneous Nephrolithotomy",[163,164,165],"Renal stones","Flexible Nephroscopy","Multi-tract",{"date":78,"type":31},{"date":145,"type":31},{"date":169,"type":22},"2028-08-30",{"name":36,"class":37},{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":50,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},"100651246","lifestyle-modification-for-erectile-dysfunction-in-men-with-metabolic-syndrome-100651246","NCT07758842","Lifestyle Modification for Erectile Dysfunction in Men With Metabolic Syndrome","Penile Hemodynamic Recovery Following a Six-Month Structured Lifestyle Modification Program in Men With Metabolic Syndrome-Associated Erectile Dysfunction: A Prospective Single-Arm Interventional Study","LIFE-MetS-ED","Inclusion Criteria:\n\n* Men aged 30-65 years.\n* Erectile dysfunction present for at least six months.\n* International Index of Erectile Function-5 score of 21 or less.\n* Metabolic syndrome diagnosed according to the International Diabetes Federation criteria.\n* Sexually active participants in a stable sexual relationship.\n* Willingness and ability to participate in the six-month lifestyle-modification program.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Erectile dysfunction primarily attributable to neurogenic, psychogenic, hormonal, or postsurgical causes.\n* Severe hypogonadism requiring immediate testosterone-replacement therapy.\n* Use of phosphodiesterase type 5 inhibitors, intracavernosal injections, vacuum erection devices, or other erectile-dysfunction treatment that cannot be discontinued before baseline assessment.\n* Significant penile anatomical abnormality that may interfere with penile duplex Doppler assessment, including Peyronie disease.\n* Previous pelvic surgery or pelvic radiotherapy likely to affect erectile function.\n* Severe or unstable cardiovascular disease that precludes sexual activity or participation in exercise-based lifestyle modification.\n* Uncontrolled diabetes mellitus, defined in the protocol as HbA1c greater than 10%.\n* Uncontrolled hypertension despite medical therapy.\n* Severe renal or hepatic impairment.\n* Active malignancy or life expectancy of less than one year.\n* Major psychiatric illness, cognitive impairment, or inability to comply with study procedures or follow-up.\n* Inability or refusal to provide written informed consent.","65 Years",{"count":181,"type":22},55,[52],"Metabolic syndrome is associated with erectile dysfunction through obesity, insulin resistance, abnormal blood lipids, high blood pressure, and impaired blood-vessel function. This study will evaluate whether a structured six-month lifestyle-modification program can improve penile blood flow and erectile function in men with metabolic syndrome-associated erectile dysfunction.\n\nEligible participants will receive dietary counseling, exercise guidance, weight-management advice, smoking-cessation counseling when applicable, sleep and sedentary-behavior advice, and repeated behavioral reinforcement. Erectile function, penile blood-flow measurements obtained by penile duplex Doppler ultrasonography, body measurements, and selected metabolic laboratory parameters will be assessed before the program and after six months.",[141,185],"Metabolic Syndrome",{"date":187,"type":31},"2026-08-14",{"date":145,"type":31},{"date":190,"type":22},"2027-11-24",{"name":36,"class":37},2,{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":50,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":216,"leadSponsor":218,"locationsCount":4},"100651820","acceptance-and-commitment-therapy-plus-physiotherapy-for-chronic-low-back-pain-100651820","NCT07766616","Acceptance and Commitment Therapy Plus Physiotherapy for Chronic Low Back Pain","Effects of Adding Acceptance and Commitment Therapy to Physiotherapy Program on Pain Catastrophizing, Stress, Disability, and Sleep Quality in Individuals With Chronic Low Back Pain","Inclusion Criteria:\n\nA\\_Aged between 18-55 years. B\\_Clinically diagnosed with non-specific chronic low back pain (CLBP). C\\_Low back pain persisting for more than 3 months.\n\nExclusion Criteria:\n\nA. History of previous spinal surgeries or invasive interventions in the lumbar region.\n\nB. Presence of \"Red Flags\" or serious underlying pathologies, such as spinal tumors, infections, or vertebral fractures.\n\nC. Current or recent (within the last 6 months) participation in structured psychological rehabilitation or behavioral therapy programs.\n\nD. Clinical evidence of neurological deficits, radiculopathy, or cauda equina syndrome.\n\nE. Pregnancy, due to the physiological changes affecting musculoskeletal mechanics.\n\nF. Severe behavioral or communication impairments preclude the ability to follow the intervention protocol or complete the self-report assessments.\n\nG. Patients who take any sleep medication or for mental health medication. H. Patients who have done physiotherapy program last 3 months.","55 Years",{"count":202,"type":22},64,[52],"This study is a randomized controlled trial (RCT) investigating whether adding Acceptance and Commitment Therapy (ACT) to standard physiotherapy provides greater benefits for adults with chronic low back pain than physiotherapy alone.\n\nA total of 60 participants will be randomly allocated into two groups: ACT plus physiotherapy and physiotherapy alone. Both groups will receive a 8-weeks program with two sessions per week. The ACT component focuses on acceptance, psychological flexibility, mindfulness, cognitive defusion, values, and committed action.\n\nThe main outcomes are pain catastrophizing, functional disability, perceived stress, and sleep quality, assessed using the PCS, ODI, PSS, and PSQI. The study aims to determine whether combining psychological and physical rehabilitation produces better outcomes than physiotherapy alone.",[206],"Low Back Pain",[208,209,210,211,212],"low back pain","sleep","Acceptance and Commitment Therapy","Exercises","Randomization","2026-08-11",{"date":187,"type":31},{"date":30,"type":22},{"date":217,"type":22},"2027-02-01",{"name":36,"class":37},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":226,"sex":46,"minAge":47,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":50,"phases":230,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100651411","phase-1-efficacy-and-safety-of-fractional-carbon-dioxide-laser-plus-topical-metformin-in-treatment-of-acanthosis-nigricans-100651411","NCT07760181","Efficacy and Safety Of Fractional Carbon Dioxide Laser Plus Topical Metformin In Treatment Of Acanthosis Nigricans","Efficacy and Safety Of Fractional Carbon Dioxide Laser Plus Topical Metformin In Treatment Of Acanthosis Nigricans: A Comparative Study","Inclusion Criteria:\n\n* \\- male or female patients aged 18-50 years\n* clinically \\& dermoscopy diagnosed acanthosis nigricans involving the neck\n* skin types iii-v\n* stable systemic condition for at least 3 months\n* willingness to comply with study protocol and follow-up\n\nExclusion Criteria:\n\n* \\- pregnancy or lactation\n* malignancy-associated acanthosis nigricans\n* active skin infection or inflammatory dermatosis at the treatment site\n* history of keloid or hypertrophic scar formation\n* photosensitivity disorders\n* use of topical or systemic treatment for acanthosis nigricans within the last 4 weeks\n* previous laser treatment to the neck within the last 6 months",true,"50 Years",{"count":229,"type":22},34,[231],"PHASE1","evaluate and compare the clinical Efficacy \\& Safety Of Fractional Carbon Dioxide (Co₂) Laser Plus Topical Metformin In Treatment Of Acanthosis Nigricans.",[234],"Acanthosis Nigricans","2026-08-07",{"date":237,"type":31},"2026-08-12",{"date":124,"type":22},{"date":240,"type":22},"2027-09-10",{"name":36,"class":37},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":50,"phases":251,"briefSummary":252,"conditions":253,"keywords":257,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100650414","clinical-and-radiographic-evaluation-of-low-sagittal-medial-ramus-osteotomy-for-treatment-of-skeletal-class-ii-and-class-iii-malocclusion-100650414","NCT07746700","Clinical and Radiographic Evaluation of Low Sagittal Medial Ramus Osteotomy for Treatment of Skeletal Class II and Class III Malocclusion","Inclusion Criteria:\n\n* Patients with skeletal Class II or Class III malocclusion requiring mandibular orthognathic surgery.\n* Age range from 18 to 45 years old.\n* Systematically healthy patients classified as ASA physical status I or II (American Society of Anesthesiologists)\n\nExclusion Criteria:\n\n* Patients with a pre-existing history of inferior alveolar nerve (IAN) sensory impairment.\n* Patients with active or severe degenerative joint disease (DJD).\n* Patients with a prior history of orthognathic surgical procedures.\n* Patients presenting with systemic diseases or conditions known to compromise normal bone healing.","45 Years",{"count":250,"type":22},11,[52],"This prospective clinical trial aims to evaluate the clinical and radiographic outcomes of the low sagittal medial ramus osteotomy-a technical modification of the conventional sagittal split osteotomy (SSO)-for treating patients with skeletal Class II and Class III malocclusions.\n\nStandard sagittal split osteotomies carry risks of complications, including unfavorable osteotomy propagation (bad splits) toward the condyle, ramus fragmentation, lingual interference of the distal segment, and inferior alveolar nerve (IAN) injury. To minimize these risks, this study utilizes a modified medial cut positioned low (below the lingula in an area with adequate marrow space) and short (terminating anterior to the lingula). This design aims to prevent osteotomy extension into the condylar region and eliminate lingual interference during segment repositioning.",[254,255,256],"Skeletal Class II Malocclusion","Skeletal Class III Malocclusion","Dentofacial Deformities",[258,259,254,255],"Orthognathic Surgery","Sagittal Split Osteotomy","2026-07-30",{"date":262,"type":31},"2026-08-05",{"date":264,"type":22},"2026-09",{"date":266,"type":22},"2027-09",{"name":36,"class":37},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":46,"minAge":4,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":38},"100646339","nailfold-capillaroscopic-changes-in-psoriasis-100646339","NCT07693595","Nailfold Capillaroscopic Changes in Psoriasis","Nailfold Capillaroscopic Changes in Psoriasis and Its Correlation With Disease Severity","Inclusion Criteria:\n\n* Patients clinically diagnosed with psoriasis.\n\nExclusion Criteria:\n\n* Patients with connective tissue diseases (e.g., systemic sclerosis, SLE)\n* Diabetes mellitus or peripheral vascular disease\n* Current smokers\n* Pregnant or lactating women\n* Recent use of vasodilators or beta-blockers\n* Manual workers exposed to vibrating tools",{"count":276,"type":22},100,"The goal of this observational study is to evaluate nailfold capillaroscopic changes in patients with psoriasis and to assess their correlation with disease severity. The study will also explore differences in capillaroscopic findings across different clinical types of psoriasis and skin phototypes (Fitzpatrick classification). The study will include patients diagnosed with psoriasis attending dermatology outpatient clinics. Participants will undergo clinical assessment and nailfold capillaroscopy to detect microvascular changes.",[279],"Psoriasis",{"date":281,"type":31},"2026-07-31",{"date":283,"type":22},"2026-08-01",{"date":285,"type":22},"2026-12-01",{"name":36,"class":37},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":292,"targetDuration":294,"studyType":23,"phases":4,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":38},"100650048","risk-factors-and-clinical-implications-of-double-j-ureteral-stent-bacterial-colonization-a-prospective-cohort-study-100650048","NCT07740811","Inclusion Criteria:\n\n* Patients undergoing temporary Double-J ureteral stent insertion.\n* Stent inserted for a standard urological indication, including ureteric stone disease, ureteral obstruction, postoperative drainage, or ureteral injury repair.\n* Planned stent removal during the study follow-up period.\n* Availability for clinical follow-up and specimen collection at insertion and removal.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Active urosepsis at the time of stent insertion.\n* Permanent or intended long-term stenting outside the study framework.\n* Concomitant nephrostomy tube or urinary diversion that may confound microbiological results.\n* Known severe immunosuppression or neutropenia if expected to substantially alter colonization risk.\n* Patients with incomplete baseline clinical data.\n* Patients lost to follow-up or whose stent could not be retrieved for microbiological analysis.\n* Refusal to participate.",{"count":293,"type":22},400,"2 Weeks","To identify the risk factors associated with bacterial colonization of Double-J ureteral stents and to evaluate its clinical implications, including bacteriuria, UTI, antimicrobial resistance, and stent-related symptoms.",[297,120],"UTI",[297,299,300,301],"Bacterial colonization","JJ stent","infection","2026-07-28",{"date":304,"type":31},"2026-08-03",{"date":306,"type":31},"2026-04-01",{"date":308,"type":22},"2028-05-01",{"name":36,"class":37},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":317,"minAge":47,"maxAge":19,"enrollmentInfo":318,"targetDuration":4,"studyType":50,"phases":320,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":338,"leadSponsor":339,"locationsCount":38},"100649880","low-intensity-shock-wave-therapy-for-refractory-overactive-bladder-in-women-100649880","NCT07739550","Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women","Therapeutic Effects of Low-Intensity Extracorporeal Shock Wave Therapy on Refractory Overactive Bladder Symptoms in Females","Inclusion Criteria:\n\n* Female participants aged 18 to 70 years.\n* Symptoms of overactive bladder with an Overactive Bladder Questionnaire 8-Item total score greater than 8.\n* Failure of behavioral therapy and medical treatment for overactive bladder.\n* Refusal of medical treatment for overactive bladder. Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Current use of medical treatment for overactive bladder.\n* Cardiac pacemaker or metallic implant in the treatment area.\n* Coagulation disorder or use of anticoagulants that cannot be temporarily discontinued.\n* Active urinary tract infection; participants may be reconsidered after successful treatment and recovery.\n* Urinary bladder stones.\n* Post-void residual urine volume greater than 100 mL.\n* Lower urinary tract surgery within the previous 6 months.\n* Previous pelvic radiation therapy.\n* History of neuropathic disease.\n* Pregnancy or planning to become pregnant.\n* Hepatic, renal, or cardiac impairment.","FEMALE",{"count":319,"type":22},40,[52],"Overactive bladder is a condition characterized by a sudden and difficult-to-control need to urinate, which may occur with frequent urination, nighttime urination, and urine leakage. Some women continue to experience these symptoms despite lifestyle changes, behavioral therapy, and medication, or they cannot tolerate or decline medical treatment.\n\nThis study will evaluate whether low-intensity extracorporeal shock wave therapy (Li-ESWT), a non-surgical treatment delivered externally over the lower abdomen, can safely improve refractory overactive bladder symptoms in women.\n\nA total of 40 women will be randomly assigned in equal numbers to receive either active Li-ESWT or a sham treatment. Both groups will attend one treatment session each week for six weeks. The sham procedure will be similar to the active treatment in positioning, session duration, and device sound but will not deliver shock wave energy.\n\nSymptoms will be assessed using the validated Arabic version of the 8-item Overactive Bladder Questionnaire (OAB-V8) before treatment and during follow-up. The main purpose of the study is to compare the change in OAB-V8 symptom score between the two groups after one month. Additional assessments at three months will include post-void residual urine volume, information from a 3-day voiding diary, the participant's overall impression of improvement, and any treatment-related adverse events.\n\nThe study hypothesis is that Li-ESWT will improve overactive bladder symptoms and quality of life compared with sham treatment.",[323],"Urinary Bladder, Overactive",[325,326,327,328,329,330,331,332,333,334,335],"Refractory Overactive Bladder","Low-Intensity Extracorporeal Shock Wave Therapy","Female Lower Urinary Tract Symptoms","Urinary Urgency","Urinary Frequency","Nocturia","Urgency Urinary Incontinence","Functional Bladder Capacity","Post-Void Residual Urine","Sham-Controlled Clinical Trial","Overactive Bladder Questionnaire, 8-Item",{"date":281,"type":31},{"date":283,"type":22},{"date":217,"type":22},{"name":36,"class":37},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":226,"sex":46,"minAge":346,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":50,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":38},"100648942","management-of-early-onset-scoliosis-by-active-apex-correction-technique-100648942","NCT07727408","Management of Early Onset Scoliosis by Active Apex Correction Technique","Inclusion Criteria:\n\n* patients with early-onset scoliosis below 10 years\n* patients not operated on before.\n\nExclusion Criteria:\n\n* Patients above 10 years.\n* Patients operated on before","1 Year","10 Years",{"count":349,"type":22},15,[52],"Early onset scoliosis is challenging cases in management .different techniques used to correct the deformity ranging between fusionlees and fusion surgery. Fusionless surgery permits developments of vertebral column and lung to avoid thoracic insufficiency syndrome. Fusion surgeries for complicated and high curves .New fusionless technique that I will use in my research is to modulate and guide the growth of the Apex of deformity through tethering the convex side and modulate the concave side and follow up the patients to see the results on their radiological and clinical parameters.",[353],"Cases of Early Onset Scoliosis","2026-07-23",{"date":356,"type":31},"2026-07-27",{"date":358,"type":31},"2023-11-25",{"date":360,"type":22},"2027-01-02",{"name":36,"class":37},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":46,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":50,"phases":369,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":38},"100626091","surgical-clinical-correlation-in-unilateral-conductive-hearing-loss-with-intact-tympanic-membrane-100626091","NCT07431125","Surgical-Clinical Correlation in Unilateral Conductive Hearing Loss With Intact Tympanic Membrane","Inclusion Criteria:\n\n* unilateral conductive hearing loss or mixed HL with intact Tympanic Membrane\n* Average Airborne Gap Above 20 decibels Exclusion Criteria\n* Sensorineural hearing loss\n* Chronic otitis media\n* TM perforation\n* Previous ear surgery",{"count":276,"type":22},[52],"Unilateral conductive hearing loss (UCHL) in the presence of an intact tympanic membrane represents a diagnostic challenge in otologic practice. In the absence of middle ear effusion or tympanic membrane pathology, stapes fixation secondary to otosclerosis is often considered the most probable diagnosis. However, although otosclerosis is traditionally regarded as a bilateral disease, clinical presentation may be unilateral due to asymmetric disease progression or subclinical contralateral involvement. Other etiologies, including congenital ossicular anomalies, ossicular discontinuity, tympanosclerosis without tympanic membrane involvement, or oval window abnormalities, may mimic otosclerosis both clinically and audiologically. Consequently, exploratory tympanotomy remains the gold standard for definitive diagnosis, allowing direct assessment of ossicular chain mobility and confirmation of stapes fixation. Correlating preoperative clinical suspicion with intraoperative findings is therefore essential to better define the true causes of unilateral conductive hearing loss with an intact tympanic membrane.",[372],"Conductive Hearing Loss, Unilateral",[374,375,376,377,378],"Otoscelrosis","Exploration Tympanotomy","stapedectomy","tympanic membrane","conductive hearing loss",{"date":380,"type":31},"2026-07-24",{"date":382,"type":31},"2026-01-01",{"date":81,"type":22},{"name":36,"class":37},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":46,"minAge":18,"maxAge":227,"enrollmentInfo":393,"targetDuration":4,"studyType":50,"phases":394,"briefSummary":395,"conditions":396,"keywords":400,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":38},"100644677","omega-3-plus-low-dose-aspirin-in-smokers-with-stage-iii-periodontitis-100644677","NCT07673185","Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis","Clinical and Biochemical Evaluation of the Effect of Omega-3 Fatty Acids Plus Low-Dose Aspirin as an Adjunct to Non-Surgical Periodontal Therapy in Smoker Patients With Stage III Periodontitis: A Randomized Double-Blind Placebo-Controlled Clinical Trial","OASP","Inclusion Criteria:\n\n* \\- Male or female smokers aged 30 to 50 years.\n* Diagnosed with Stage III periodontitis according to the 2017 World Workshop classification.\n* Probing pocket depth (PPD) ≥ 5 mm.\n* Clinical attachment loss (CAL) ≥ 5 mm.\n* Presence of at least 20 natural teeth.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* \\- Systemic diseases affecting periodontal health.\n* Pregnancy or lactation.\n* Periodontal treatment within the previous 6 months.\n* Use of antibiotics or anti-inflammatory drugs within the previous 6 months.\n* Allergy or hypersensitivity to omega-3 fatty acids or aspirin.\n* Long-term anticoagulant therapy.\n* History of gastric ulcer or bleeding disorders.\n* Participation in another clinical trial within the previous 3 month",{"count":319,"type":22},[52],"This randomized double-blind placebo-controlled clinical trial aims to evaluate the clinical and biochemical effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct to scaling and root planing (SRP) in smoker patients with Stage III periodontitis. The study compares test and control groups regarding periodontal clinical parameters and gingival crevicular fluid interleukin-1 beta (IL-1β) levels Or other inflammatory markers that will be determined later at baseline, 3 months, and 6 months following treatment",[397,398,399],"Periodontal Disease","Periodontitis (Stage 3)","Smoking Behaviors",[401,402,403],"omega 3","smoker","stage 3","2026-07-06",{"date":406,"type":31},"2026-07-08",{"date":408,"type":31},"2025-01-15",{"date":410,"type":22},"2026-10-30",{"name":36,"class":37},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":226,"sex":46,"minAge":47,"maxAge":248,"enrollmentInfo":420,"targetDuration":4,"studyType":50,"phases":422,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":38},"100645064","effect-of-co-enzyme-q10-and-vitamin-c-alone-or-in-combination-after-a-surgical-gingival-depigmentation-100645064","NCT07677826","Effect of Co-enzyme Q10 and Vitamin C Alone or in Combination After a Surgical Gingival Depigmentation","Ffect of Co-enzyme Q10 and Vitamin C Alone or in Combination After a Surgical Gingival Depigmentation a Randomized Clinical Study","Effect of Coe","Inclusion Criteria:\n\n* Systemically healthy patient of both genders aged from 18-45 years.\n* Presence of bilateral physiologic gingival pigmentation in the anterior maxillary or mandibular region DOPI grades III-IV only.\n* Good oral hygiene.\n* Thick gingival phenotype.\n\nExclusion Criteria:\n\n* Patient clinically diagnosed with periodontitis.\n* Pregnant or lactating females.\n* Patient with previous treatment of gingival hyperpigmentation.\n* History of hypersensitivity to any study material.\n* Patients who are active or previous smokers.",{"count":421,"type":22},20,[52],"This study aims to assess the clinical effectiveness of Co-enzyme Q10 and Vitamin C, applied individually or in combination after surgical gingival depigmentation.",[425,426],"Depigmentation Treatment","Depigmentation","2026-06-29",{"date":429,"type":31},"2026-07-01",{"date":431,"type":31},"2026-03-02",{"date":433,"type":22},"2026-12-20",{"name":36,"class":37},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":46,"minAge":443,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":50,"phases":447,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":38},"100644916","twin-block-and-lipus-for-tmj-outcomes-in-skeletal-class-ii-patients-100644916","NCT07676695","Twin-Block and LIPUS for TMJ Outcomes in Skeletal Class II Patients","Evaluation of the Efficacy of Early Treatment of Skeletal Class II Patients With Twin-block in Conjunction With Low Intensity Pulsed Ultrasound on Temporomandibular Joint Region: a Prospective Clinical Trial","AlAzharU","Inclusion Criteria:\n\n* Skeletal class II due to retrognathic mandible.\n* Angle's class II Molar relationship.\n* All patients involved in the study were in stages II and III based on the modified cervical vertebral maturation stages (CVMS) by Bacetti et al.5\n* Proclined upper incisors\n* Increased overjet \\> 5 mm.\n* Aligned lower arch or average inclination\n* Minimal crowding of lower arch.\n* No history of previous orthodontic treatment.\n\nExclusion Criteria:\n\n* Skeletal class II due to prognathic maxilla.\n* Patient with gross facial asymmetry.\n* Previous orthodontic or orthopedic treatment.\n* Clinical signs and symptoms of any Temporomandibular joint disorders.\n* Increased anterior facial vertical dimension.\n* Poor oral hygiene.","10 Months","14 Months",{"count":446,"type":22},24,[52],"Evaluation of the efficacy of early treatment of skeletal class II patients with twin-block in conjunction with low intensity pulsed ultrasound on temporomandibular joint region: a prospective clinical trial",[450],"CLASS II DIVISION 1 MALOCCLUSION",[452,453,454,455],"Class II div 1","Twin Block","CBCT","LIPUS","2026-06-27",{"date":458,"type":31},"2026-06-30",{"date":460,"type":31},"2026-06-18",{"date":147,"type":22},{"name":36,"class":37},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":226,"sex":317,"minAge":47,"maxAge":248,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":472,"conditions":473,"keywords":477,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":4},"100645234","pupillary-light-reflex-to-predict-post-spinal-hypotension-in-elective-cesarean-delivery-100645234","NCT07678723","Pupillary Light Reflex to Predict Post-Spinal Hypotension in Elective Cesarean Delivery","Pupillary Light Reflex for Predicting Hypotension Risk After Spinal Anesthesia for Elective Cesarean Section: A Prospective Observational Cohort Study","Inclusion Criteria:\n\nASA II Term pregnancy ≥37 weeks Singleton pregnancy Elective cesarean section Age 18-45 years Written informed consent\n\nExclusion Criteria:\n\nEmergency cesarean section Hypertensive disorders Diabetes mellitus Cardiovascular disease Neurological or autonomic disorders Ophthalmic disease Medications affecting autonomic function BMI \\>40 kg\u002Fm² Failed spinal anesthesia",{"count":471,"type":22},200,"This prospective observational cohort study investigates whether pre-anesthetic pupillary light reflex (PLR) parameters can predict the risk of hypotension following spinal anesthesia in women undergoing elective cesarean section. Spinal anesthesia-induced hypotension is common, with reported incidence rates of 50-90%, and current predictors such as baseline blood pressure and BMI have limited accuracy. PLR, a sensitive marker of autonomic nervous system balance, may offer a simple, objective, and non-invasive tool for identifying patients at higher risk. The study evaluates pupillary reaction latency and other PLR parameters and correlates them with post-spinal blood pressure changes to determine their predictive value.",[474,475,476],"Hypotension","Spinal Anesthesia","Cesarean Delivery",[478,479,475,474,480,481],"Pupillary Light Reflex","Pupillometry","Cesarean Section","Obstetric Anesthesia","2026-06-25",{"date":429,"type":31},{"date":485,"type":22},"2026-06-28",{"date":487,"type":22},"2026-10-31",{"name":36,"class":37},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":50,"phases":499,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100644446","ncmt-technique-and-jodhpur-technique-and-excimer-laser-in-treatment-of-non-vitiligo-leucoderma-100644446","NCT07662915","NCMT Technique and Jodhpur Technique and Excimer Laser in Treatment of Non Vitiligo Leucoderma","Efficacy and Safety of Melanocyte Keratinocyte Transplantation Procedure Plus 308-nm Excimer Laser in the Treatment of Non-Vitiligo Leukoderma","Inclusion Criteria:\n\n* Age 18 to 60 years.\n* Clinically diagnosed stable non-vitiligo leukoderma.\n* Stable lesion(s) for at least 6 months with no progression.\n* Inadequate response to conventional medical therapy.\n* Presence of two comparable lesions\n* Willingness to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Vitiligo or suspected active vitiligo.\n* History of keloid or hypertrophic scar formation.\n* Active infection at donor or recipient sites.\n* Bleeding disorders or anticoagulant therapy that cannot be safely discontinued.\n* Pregnancy or lactation.\n* Immunosuppression or uncontrolled systemic disease.\n* Inability to comply with follow-up visits.\n* Unrealistic expectations regarding treatment outcome.","60 Years",{"count":498,"type":22},22,[52],"This study aims to compare the efficacy and safety of Melanocyte Keratinocyte Transplantation Procedure (MKTP) combined with 308-nm excimer laser versus Jodhpur technique combined with 308-nm excimer laser in the treatment of stable non-vitiligo leukoderma. Twenty-two patients with stable depigmented lesions will be enrolled. In each patient, two comparable lesions will be treated using different techniques. Clinical outcomes including percentage of repigmentation, color match, time to onset of repigmentation, complications, and histological changes will be assessed during follow-up to determine the optimal surgical treatment approach for non-vitiligo leukoderma.",[502],"Leukoderma","2026-06-17",{"date":505,"type":31},"2026-06-23",{"date":429,"type":22},{"date":508,"type":22},"2027-09-01",{"name":36,"class":37},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":226,"sex":46,"minAge":70,"maxAge":47,"enrollmentInfo":517,"targetDuration":4,"studyType":50,"phases":519,"briefSummary":520,"conditions":521,"keywords":523,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":529,"leadSponsor":531,"locationsCount":4},"100632493","bilogical-assesment-during-intrusion-of-lower-incisors-100632493","NCT07514403","Bilogical Assesment During Intrusion of Lower Incisors","Assessment of the Biological Response of the Corticision During Intrusion of Lower Incisors A Prospective Clinical Study","Inclusion Criteria:\n\n* Patients requiring extraction-based orthodontic treatment\n* Presence of deep overbite requiring lower incisor intrusion\n* Age range: 18-30 years\n* Good general health\n* Good oral hygiene\n\nExclusion Criteria:\n\n* Systemic diseases affecting bone metabolism\n* Previous orthodontic treatment\n* Periodontal disease\n* Smoking\n* Pregnancy or lactation",{"count":518,"type":22},16,[52],"biological assesment during intrusion of lower incisors",[522],"Orthodontic Treatment Efficiency",[524],"Orthodontics Malocclusion Corticision","2026-06-13",{"date":527,"type":31},"2026-06-16",{"date":283,"type":22},{"date":530,"type":22},"2027-08",{"name":36,"class":37},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":226,"sex":46,"minAge":539,"maxAge":227,"enrollmentInfo":540,"targetDuration":4,"studyType":50,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":38},"100567227","erythropoietin-gel-effect-on-dental-implant-stability-100567227","NCT06665451","Erythropoietin Gel Effect on Dental Implant Stability","Evaluation of Erythropoietin Gel Effect on Stability of Immediate Implant ( Clinical and Radiographical Study )","Inclusion Criteria:\n\n* All patients Should have nonrestorable teeth in the anterior maxilla indicated for extraction and seeking implant placement.\n* Good general periodontal health and maintenance.\n\nExclusion Criteria:\n\n* Heavy smokers who smoke more than ten cigarettes per day\n* Acute infected socket\n* Ant socket with wall defect.\n* Pregnency\n* Local or systemic conditions that will interfere with bone healing (uncontrolled diabetes mellitus or human immune deficiency virus infections, resonance therapy), bone disorders (hyperparathyroidism, osteoporosis, or Paget's disease.\n* Patients who had subjected to intravenous and\u002For oral bisphosphonate therapy.","20 Years",{"count":446,"type":22},[52],"* Achieving and maintaining long-term osseointegration for dental implants is a key objective in the field of dentistry. The success of osseointegration is influenced by the surface treatment applied to dental implants. Numerous coating techniques have been developed to improve and speed up osseointegration.\n* The aim of the current study is to assess immediate dental implant stability coated with erythropoietin gel, both clinically and radiographically.\n* Materials and Methods: We conducted a randomized controlled clinical trial.The sample will include patients demanding immediate implant treatment in the anterior maxilla . Patients will be randomly allocated into the two groups of the study. The group A will be treated with erythropoietin gel coated dental implant immediately after extraction of non restorable teeth in the anterior maxilla . Group B will be treated with non coated dental implant immediately after extraction of non restorable teeth in the anterior maxilla .\n* The primary outcome variable will be implant stability and the secondary outcome will be crestal marginal bone level and bone density around implants. It will be measured at time of implant placement and reevaluated after 6-months .",[544],"Osseointegration","2026-05-15",{"date":547,"type":31},"2026-05-18",{"date":549,"type":31},"2025-03-15",{"date":551,"type":22},"2026-07",{"name":36,"class":37},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":46,"minAge":561,"maxAge":562,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":192},"100575083","the-relation-between-oral-hygiene-and-microbial-load-in-the-oral-cavity-after-restoring-primary-molars-with-two-types-of-ready-made-crowns-100575083","NCT06767670","The Relation Between Oral Hygiene and Microbial Load in the Oral Cavity After Restoring Primary Molars With Two Types of Ready-made Crowns","Evaluation of Oral Hygiene Status in Correlation With Microbial Load in the Oral Cavity Following Restorations of Primary Molars Using Stainless Steel and Bioflex Crowns (Clinical Randomized Trial)","bioflex crown","Inclusion Criteria:\n\n* Participants aged between 4 and 8 years.\n* Pulp therapy treated primary molars on the contralateral side, requiring a full coverage restoration (split-mouth technique).\n* No history of any antibiotic consumption 2 weeks before the procedure.\n* No history of fluoride application 2 weeks before the procedure.\n\nExclusion Criteria:\n\n* Special children with physical disabilities or emotional disturbances.\n* Children are diagnosed with systemic diseases.\n* Grossly destructed teeth with non-restorable crown structure.\n* Primary teeth with shedding or pathological tooth mobility.","4 Years","8 Years",{"count":319,"type":22},"Following the restoration of primary molars with stainless steel and bioflex crowns, an evaluation of the current state of oral hygiene in relation to the amount of microorganisms and gingival health in the oral cavity will be carried out.",[566,567],"Carious Lesion","Ready-made Crowns",[569,570],"primary crowns,","oral health","2026-05-11",{"date":573,"type":31},"2026-05-12",{"date":575,"type":22},"2026-10-05",{"date":577,"type":22},"2027-10-01",{"name":36,"class":37},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":539,"maxAge":587,"enrollmentInfo":588,"targetDuration":4,"studyType":50,"phases":590,"briefSummary":591,"conditions":592,"keywords":595,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":38},"100636911","modulation-of-periapical-inflammation-following-nano-sized-intracanal-medication-a-randomized-controlled-clinical-trial-100636911","NCT07571837","Modulation of Periapical Inflammation Following Nano-sized Intracanal Medication. A Randomized Controlled Clinical Trial","Modulation of Periapical Inflammation Following Nano-Calcium Hydroxide and Nano-Chitosan Intracanal Medications in Endodontic Retreatment Cases: A Randomized Controlled Clinical Trial","Nano-Chitosan","Inclusion Criteria:\n\nPatients have single rooted teeth with root canal form type I. Have previous endodontic therapy with failure. Have periapical radiolucency (PAI score of 3 or 4). Asymptomatic patients who had no pain or swelling, had a negative response to palpation and percussion.\n\nExclusion Criteria:\n\nPatients who had received antibiotic therapy within the past 3 months. Pregnancy and lactation. Systemic disease. Physical or mental disability. Non-restorable teeth. Any signs of resorption, immature roots, fracture, sinus tract and dental anomaly","40 Years",{"count":589,"type":22},63,[52],"The main cause of endodontic disorders is microbial infection. From the infected pulp tissue, microorganisms can penetrate into the deeper layers of root dentine and propagate a periapical tissue through the apical foramen and lateral canals causing apical periodontitis. Apical periodontitis is an inflammatory condition affecting the periapical area of teeth with a global prevalence of 52% among individuals and 5% at tooth level. At the periapical region, microbes and their products encounter the host immune defense. Innate immune cells combat bacteria through phagocytosis and release anti-microbial substances, while adaptive immune cells initiate both cell-mediated and humoral immune responses. This immune activation also stimulates osteoclasts, leading to bone resorption and creating space for the inflammatory cells' infiltration . During periapical inflammation, immune cells migrate to the periapical area, where they release pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), along with anti-inflammatory cytokines like interleukin-10 (IL-10). These cytokines play crucial roles in modulating inflammation and tissue repair.\n\nMicroRNAs (miRNAs) are evolutionarily conserved small (18-22 nucleotides) single-stranded, noncoding RNAs. It has been well acknowledged that miRNAs influence gene expression at the posttranscriptional level by targeting mRNA 3'-untranslated regions (3'-UTRs). Accumulating evidence has suggested that miRNA expression is related to the clinical and biological features of diverse diseases, and they can be potential biomarkers for diagnosis, treatment, and prognosis. miRNAs have revealed their critical roles in regulating various cellular functions, including proliferation, apoptosis, differentiation, metabolism, and tumorigenesis, by targeting specific mRNAs.\n\nMiR-146a regulates innate immunity, inflammatory responses, and the antiviral pathway. Changes in miR-146a expression have been noted in many human diseases, including autoimmune disorders and cancers. In addition, miR-146a is an important biomarker of disease diagnosis, prevention, and treatment. It is a negative regulator of inflammatory responses by suppressing target gene expression. However, limited data is available regarding the functional role of miR-146a in modulating the inflammatory response of periapical tissues following root canal disinfection in endodontic retreatment cases.\n\nEliminating microorganisms is the primary objective of root canal therapy in order to create an environment as free of bacteria as possible. However, not all root canal treatments are completely successful, and in some cases, the infection persists leading to development of secondary apical periodontitis in previously treated teeth.\n\nDisinfecting the root canal during retreatment is significantly more challenging due to the presence of persistent microorganisms that have settled in the root canal system. These microbes are often resistant to standard irrigations and antimicrobial agents leading to the formation of periradicular lesions. Such bacteria can survive for extended periods around the previously filled root canals. Sodium hypochlorite (NaOCl) is the most widely used irrigant in root canal therapy due to its strong antibacterial effect and its ability to dissolve organic substances. Effective canal cleaning is difficult to achieve without the use of NaOCl at a sufficiently high concentration. However, NaOCl has several drawbacks, including its cytotoxicity which can lead to tissue damage and patient symptoms. Additionally, its strong oxidizing nature negatively affects the mechanical properties of dentin such as microhardness and elastic modulus. NaOCl should be used with caution in endodontic procedures to prevent hypochlorite accidents.\n\nCalcium hydroxide (Ca (OH)2) is the most widely utilized intracanal medication. It has the potential to dissolve tissue, acts as a physical barrier and generates hydroxyl ions, creating an extremely alkaline environment. It has been shown to be quite effective in the treatment of teeth with persistent periapical lesions. To provide optimal endodontic treatment, the root canal system should be thoroughly cleaned of soft-tissue debris, smear layer, and bacteria. Nanoparticles (NPs) have unique characteristics such as smaller sizes, increased surface area to volume ratio, and higher chemical reactivity and charge density leading to greater interaction with the environment and negatively charged bacterial cells, compared to their bulk counterparts. These advantages can be used to design highly anti-microbial agents with maximal therapeutic efficacy and minimal side effects.",[593,594],"Post-operative Pain","Periapical Inflammation",[594,596,585,597],"Nano-Calcium Hydroxide","Endodontic Retreatment","2026-05-03",{"date":600,"type":31},"2026-05-06",{"date":602,"type":31},"2026-02-01",{"date":604,"type":22},"2027-01-30",{"name":36,"class":37},""]